STADA Specialty and Biosimilars:
Opening doors to more affordable, life-changing treatments

At STADA, Thornton & Ross, we continue to offer unrivalled expertise and outstanding value in Specialty Pharmaceuticals. This exciting area of medicine offers various ways to treat patients. Besides OTC and Generics, we focus on specialties like biosimilars, in therapeutic areas of nephrology, oncology, diabetes, and ophthalmology.

  • Icon 1

    2006

    The introduction of the first
    biosimilar in clinical use
  • Icon 2

    >30

    Biosimilars approved for use in the
    EU to date as of March 2019
  • Icon 3

    20 to 25%

    Savings compared to
    reference products

Kinpeygo® (targeted-release budesonide)

Kinpeygo® (targeted-release budesonide) - the first and only disease-modifying treatment approved across Europe and by NICE specifically for use in IgA nephropathy1,2

Kinpeygo® (targeted-release budesonide) is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with urine protein-to-creatinine ratio (UPCR) ≥ 1.5g/gram.

API - Prescribing Information can be found here
Zoomed Eye

XIMLUCI® (ranibizumab)

Our first ophthalmology biosimilar, ranibizumab is a biological medicine that is injected into the eye. XIMLUCI® is the ranibizumab biosimilar from STADA Thornton and Ross.3

Ximluci® is indicated for adult patients, treatment of: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular oedema (DME); proliferative diabetic retinopathy (PDR); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); visual impairment due to choroidal neovascularisation (CNV).

API - Prescribing Information can be found here
Holding Hands

MOVYMIA®(teriparatide)

Movymia® the teriparatide biosimilar from Thornton & Ross, STADA. Movymia® is indicated for adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.4

API - Prescribing Information can be found here

Man Looking Mobile

Lets stay connected!

Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?

STADA: Caring for people’s health as a trusted partner STADA is a leading European company, established by physicians and pharmacists. Manufacturing and distributing pharmaceuticals for more than 125 years.

Key Facts:

STADA biosimilars: Making effective medicine accessible

Four successful biosimilars in market, and an additional five in development • More than 20 years of experience in biosimilars and a continuously expanding portfolio, including adalimumab, bevacizumab, teriparatide and epoetin • Building on the innovation of biological medicines and providing lower-priced alternatives to reference products.

Biosimilars – a lifeline for people with unmet medical needs:

  • Icon 5

    Demonstrate equivalent biological activity to their corresponding reference drugs

  • Icon 5

    Improve cost-effectiveness

  • Icon 5

    Provide alternatives for decision makers (e.g. prescribers, regulators, payers, policymakers)

  • Icon 5

    Enhance treatment accessibility for patients

Our biosimilars enable improved access to treatment
for patients across a broad range of indications

What is a Biosimilar?

A biosimilar is a biologic that is highly similar to another biologic medicine:5
  • Icon 6
    Large molecule with
    a complex structure
  • Icon 7
    Produced from
    living cells
  • Icon 8
    Strictly regulated
    biomanufacturing and
    quality control
Biosimilars are approved according to the same strict standards of safety, efficacy and tolerability as other medicines:5
  • Icon 9
    Undergo clinical
    studies
  • Icon 10
    Manufactured in
    licensed facilities
  • Icon 11
    Approved using the same
    regulatory pathway as
    reference product
Biosimilars have been trusted medicines in Europe for over 15 years, since the first European biosimilar approval in 20065

NHS BIOSIMILAR ADOPTION GUIDANCE6

NHS England and NHS Improvement supports the appropriate use of biosimilar medicines which will drive greater competition and release cost savings to support the treatment of an increasing number of patients and the uptake of new and innovative medicines.

  • 90%

    At least 90% of new patients will be prescribed the best value biological medicine within 3 months of launch of a biosimilar medicine

  • 80%

    At least 80% of existing patients within 12 months, or sooner if possible.

This guidance is designed to support the NHS to achieve this.

Excerpt from NHS Comissioning framework for biological medicines6
See full NHS report here

3 persons
Laptop Home Banner Text

Click for more information on Biosimilars

References

1. European public assessment report (EPAR) Kinpeygo. EMA/570757/2022, last revised 05/2022. 2. Overview | Targeted-release budesonide for treating primary IgA nephropathy | Guidance | NICE. https://www.nice.org.uk/guidance/ta937 (Published: 20 December 2023). 3. XIMLUCI (ranibizumab) Summary of Product Characteristics. January 2023. Available at: https://www.medicines.org.uk/emc/product/14461/smpc. Accessed July 2023. 4. Movymia 20 micrograms/80 microliters solution for injection Summary of Product Characteristics (SmPC), Available at: https://www.medicines.org.uk/emc/product/10780 (accessed November 2022). 5. Biosimilar Medicinces Group. Biosimilar Medicines Handbook. 3rd edition 2016. Available at: https://www.medicinesforeurope.com/wp-content/uploads/2016/04/BIOSIMILARMEDICINES-HANDBOOK_INT_web_links2.pdf. Last accessed March 2024; 6. Commissioning framework for biological medicines (including biosimilar medicines) https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf. Last accessed May 2023.

Information

For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MULT-122(1) | Date of Preparation: February 2024